Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Egalet Corporation (EGLT) Share Price

Media stories about Egalet Corporation (NASDAQ:EGLT) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Egalet Corporation earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 45.3735323933038 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

Egalet Corporation (EGLT) opened at 1.46 on Wednesday. Egalet Corporation has a 52 week low of $1.01 and a 52 week high of $10.00. The company has a 50-day moving average of $1.22 and a 200-day moving average of $2.68. The stock’s market cap is $38.34 million.

Egalet Corporation (NASDAQ:EGLT) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.94) by ($0.10). The company had revenue of $6.26 million during the quarter, compared to analysts’ expectations of $6.68 million. Egalet Corporation had a negative return on equity of 607.49% and a negative net margin of 444.50%. The firm’s revenue was up 81.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.97) EPS. On average, analysts predict that Egalet Corporation will post ($2.75) EPS for the current fiscal year.

A number of brokerages recently issued reports on EGLT. Cantor Fitzgerald set a $8.00 price target on shares of Egalet Corporation and gave the stock a “buy” rating in a research note on Thursday, June 8th. ValuEngine downgraded shares of Egalet Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. JMP Securities decreased their price target on shares of Egalet Corporation from $15.00 to $6.00 and set a “market outperform” rating for the company in a research note on Friday, July 14th. Guggenheim set a $7.00 price target on shares of Egalet Corporation and gave the stock a “buy” rating in a research note on Monday, August 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $6.00 price target (down previously from $14.00) on shares of Egalet Corporation in a research note on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $6.50.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Egalet Corporation (EGLT) Share Price” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at

About Egalet Corporation

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

Insider Buying and Selling by Quarter for Egalet Corporation (NASDAQ:EGLT)

Receive News & Ratings for Egalet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corporation and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply